Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Deferred Tax Liability (2023 - 2025)

Rein Therapeutics (RNTX) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 46.72% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.8 million, a 46.72% decrease, with the full-year FY2024 number at $1.8 million, down 46.72% from a year prior.
  • Non-Current Deferred Tax Liability was $1.8 million for Q3 2025 at Rein Therapeutics, roughly flat from $1.8 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.3 million in Q4 2023 to a low of $1.8 million in Q4 2024.
  • A 3-year average of $2.5 million and a median of $2.5 million in 2023 define the central range for Non-Current Deferred Tax Liability.
  • Biggest YoY gain for Non-Current Deferred Tax Liability was 46.72% in 2024; the steepest drop was 46.72% in 2024.
  • Rein Therapeutics' Non-Current Deferred Tax Liability stood at $3.3 million in 2023, then crashed by 46.72% to $1.8 million in 2024, then changed by 0.0% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Non-Current Deferred Tax Liability are $1.8 million (Q3 2025), $1.8 million (Q2 2025), and $1.8 million (Q1 2025).